Advertisement

Design and Implementing Pharmacogenomics Study in Cancer

  • María Luisa Romero Lagunes
  • Francisco Emilio Vera BadilloEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1168)

Abstract

The advances in technology has shifted healthcare from a “one size fits all” model to focus on personalized therapy. Understanding the relationship of genome variations and its effect on drug response has led to individualized drug selection, maximizing drug efficacy and improving toxicity profile. The developments in pharmacogenomics has led to the discovery of predictive and prognostic biomarkers, and has transformed cancer research leading to the creation of pharmacogenomics databases. While challenges associated with the implementation of pharmacogenomics based medicine exist, integrating data amongst collaborative networks will be crucial for researchers to identify all the functional elements of the human genome sequence. Future advances in the area of pharmacogenomics research will eventually lead to the identification of the right therapeutic drug for the right patient.

Keywords

Pharmacogenetics Health-care system Personalized medicine Computer-based systems Point-of-care method Germline mutations, somatic mutations Whole exome sequencing Randomized trials Molecular tumor board 

References

  1. 1.
    Klein ME, Parvez MM, Shin JG (2017) Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci 106(9):2368–2379.  https://doi.org/10.1016/j.xphs.2017.04.051CrossRefPubMedGoogle Scholar
  2. 2.
    Schuck RN, Grillo JA (2016) Pharmacogenomic biomarkers: an FDA perspective on utilization in biological product labeling. AAPS J 18(3):573–577.  https://doi.org/10.1208/s12248-016-9891-4CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Van Der WCH, Cecchin E, Cheung KC, Cl D (2017) Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther 101(3):341–358.  https://doi.org/10.1002/cpt.602CrossRefGoogle Scholar
  4. 4.
    Filipski KK, Mechanic LE, Long R, Freedman AN (2014) Pharmacogenomics in oncology care. Front Genet 5(APR):1–5.  https://doi.org/10.3389/fgene.2014.00073CrossRefGoogle Scholar
  5. 5.
    Agúndez JAG, Esguevillas G, Amo G, García-Martín E (2014) Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs. Front Pharmacol 5:1–4.  https://doi.org/10.3389/fphar.2014.00188CrossRefGoogle Scholar
  6. 6.
    Caraballo PJ, Hodge LS, Bielinski SJ et al (2017) Multidisciplinary model to implement pharmacogenomics at the point of care. Genet Med 19(4):421–429.  https://doi.org/10.1038/gim.2016.120CrossRefPubMedGoogle Scholar
  7. 7.
    Dickmann LJ, Ware JA (2016) Pharmacogenomics in the age of personalized medicine. Drug Discov Today Technol 21-22:11–16.  https://doi.org/10.1016/j.ddtec.2016.11.003CrossRefPubMedGoogle Scholar
  8. 8.
    Relling MV, Evans WE (2015) Pharmacogenomics in the clinic. Nature 526(7573):343–350.  https://doi.org/10.1038/nature15817CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hess GP, Fonseca E, Scott R, Fagerness J (2015) Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genet Res (Camb) 97:e13.  https://doi.org/10.1017/S0016672315000099CrossRefGoogle Scholar
  10. 10.
    Moyer AM, Caraballo PJ (2017) The challenges of implementing pharmacogenomic testing in the clinic. Expert Rev Pharmacoeconomics Outcomes Res 17(6):567–577.  https://doi.org/10.1080/14737167.2017.1385395CrossRefGoogle Scholar
  11. 11.
    Dunnenberger HM, Crews KR, Hoffman JM et al (2015) Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol 55(1):89–106.  https://doi.org/10.1146/annurev-pharmtox-010814-124835CrossRefPubMedGoogle Scholar
  12. 12.
    Volpi S, Bult CJ, Chisholm RL et al (2018) Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clin Pharmacol Ther 103:778–786.  https://doi.org/10.1002/cpt.1048CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mangat P TAPUR: testing the use of food and drug administration (FDA) approved drugs that target a specific abnormality in a tumor gene in people with advanced stage cancer – full text view – ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02693535. Accessed June 22 2018
  14. 14.
    Crawford K ASCO’s TAPUR study continues its expansion of sites, participants, and collaborators|ASCO. https://www.asco.org/about-asco/press-center/news-releases/asco’s-tapur-study-continues-its-expansion-sites-participants. Accessed June 22 2018
  15. 15.
    Canadian Cancer Trials Group Canadian profiling and targeted agent utilization trial (CAPTUR) – full text view – ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03297606. Accessed June 22 2018
  16. 16.
    Skamene T, Siu LL, Renouf DJ, Laskin JJ, Bedard PL, Jones SJM, Ferrario C, Whitlock J, Petrie J, Patrick Sullivan ERM Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): a phase II basket precision medicine trial. |2018 ASCO annual meeting abstracts. http://abstracts.asco.org/214/AbstView_214_219037.html. Accessed June 22 2018
  17. 17.
    Levy KD, Decker BS, Carpenter JS et al (2014) Prerequisites to implementing a pharmacogenomics program in a large health-care system. Clin Pharmacol Ther 96(3):307–309.  https://doi.org/10.1038/clpt.2014.101CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rosenman MB, Decker B, Levy KD, Holmes AM, Pratt VM, Eadon MT (2017) Lessons learned when introducing pharmacogenomic panel testing into clinical practice. Value Health 20(1):54–59.  https://doi.org/10.1016/j.jval.2016.08.727CrossRefPubMedGoogle Scholar
  19. 19.
    Levy KD, Decker BS, Carpenter JS et al Prerequisites to implementing a pharmacogenomics program in a large health-care system. Clin Pharmacol Ther.  https://doi.org/10.1038/clpt.2014.101CrossRefGoogle Scholar
  20. 20.
    Hinderer M, Boerries M, Haller F et al (2017) Supporting molecular tumor boards in molecular-guided decision-making -the current status of five German university hospitals. Stud Health Technol Inform 236:48–54.  https://doi.org/10.3233/978-1-61499-759-7-48CrossRefPubMedGoogle Scholar
  21. 21.
    Hinderer M, Boeker M, Wagner SA et al (2017) Integrating clinical decision support systems for pharmacogenomic testing into clinical routine- a scoping review of designs of user-system interactions in recent system development. BMC Med Inform Decis Mak 17(1):1–14.  https://doi.org/10.1186/s12911-017-0480-yCrossRefGoogle Scholar
  22. 22.
    Tsang H, Addepalli K, Davis SR (2017) Resources for interpreting variants in precision genomic oncology applications. Front Oncol 7(September):1–10.  https://doi.org/10.3389/fonc.2017.00214CrossRefGoogle Scholar
  23. 23.
    Korngiebel DM, Thummel KE, Burke W (2017) Implementing precision medicine: the ethical challenges. Trends Pharmacol Sci 38(1):8–14.  https://doi.org/10.1016/j.tips.2016.11.007CrossRefPubMedGoogle Scholar
  24. 24.
    Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, Klein TE (2016) Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Heal Pharm 73(23):1977–1985.  https://doi.org/10.2146/ajhp150977CrossRefGoogle Scholar
  25. 25.
    Drozda K, Pacanowski MA (2017) Clinical trial designs to support clinical utility of Pharmacogenomic testing. Pharmacotherapy 37(9):1000–1004.  https://doi.org/10.1002/phar.1971CrossRefPubMedGoogle Scholar
  26. 26.
    Amstutz U, Henricks LM, Offer SM et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for Dihydropyrimidine dehydrogenase genotype and Fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210–216.  https://doi.org/10.1002/cpt.911CrossRefPubMedGoogle Scholar
  27. 27.
    Goetz MP, Sangkuhl K, Guchelaar HJ et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther 00(00):1–8.  https://doi.org/10.1002/cpt.1007CrossRefGoogle Scholar
  28. 28.
    Bell GC, Caudle KE, Whirl-Carrillo M et al (2017) Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 102(2):213–218.  https://doi.org/10.1002/cpt.598CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yan L, Zhang W (2018) Precision medicine becomes reality—tumor type-agnostic therapy. Cancer Commun 38(1):6.  https://doi.org/10.1186/s40880-018-0274-3CrossRefGoogle Scholar
  30. 30.
    Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 413(July):409–413CrossRefGoogle Scholar
  31. 31.
    ASCO post FDA accepts larotrectinib new drug application and grants priority review – the asco post. http://www.ascopost.com/News/58886. Accessed June 22 2018
  32. 32.
    Sparano JA, Gray RJ, Makower DF et al (2015) Prospective validation of a 21-gene expression assay in breast Cancer. N Engl J Med 373(21):2005–2014.  https://doi.org/10.1056/NEJMoa1510764CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Sparano JA, Gray RJ, Makower DF et al (June 2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast Cancer. N Engl J Med 379:111–121.  https://doi.org/10.1056/NEJMoa1804710CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Onitilo AA, McCarty CA, Wilke RA et al (2009) Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 115(3):643–650.  https://doi.org/10.1007/s10549-008-0264-2CrossRefPubMedGoogle Scholar
  35. 35.
    Ingle JN (2010) Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations. Breast Cancer Res 12(SUPPL. 4):6–8.  https://doi.org/10.1186/bcr2746CrossRefGoogle Scholar
  36. 36.
    Mukherjea D, Rybak LP (2011) Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 12(7):1039–1050.  https://doi.org/10.2217/pgs.11.48CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    FDA ABEMACICLIB highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf. Accessed 23 June 2018
  38. 38.
    FDA KADCYLA highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125427s096lbl.pdf. Published 2016. Accessed 23 June 2018
  39. 39.
    FDA GILOTRIB highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf. Published 2018. Accessed 23 June 2018
  40. 40.
    FDA ALECTINIB highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Published 2018. Accessed 23 June 2018
  41. 41.
    FDA TECENTRIQ (atezolizumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s010lbl.pdf#page=27. Published 2018. Accessed 23 June 2018
  42. 42.
    FDA CDER. BAVENCIO® (avelumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s002lbl.pdf. Published 2017. Accessed 23 June 2018
  43. 43.
    FDA CDER. ALUNBRIG (brigatinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf. Published 2017. Accessed 23 June 2018
  44. 44.
    FDA CDER. COMETRIQ® (cabozantinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203756s005lbl.pdf. Published 2018. Accessed 23 June 2018
  45. 45.
    FDA XELODA (capecitabine) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020896s039lbl.pdf. Published 2016. Accessed 23 June 2018
  46. 46.
    FDA ZYKADIA® (ceritinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205755s010lbl.pdf. Published 2017. Accessed 23 June 2018
  47. 47.
    FDA ERBITUX® (cetuximab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125084s269lbl.pdf. Published 2018. Accessed 23 June 2018
  48. 48.
    FDA CDER. CISplatin highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdf. Published 2015. Accessed 23 June 2018
  49. 49.
    FDA COTELLIC® (cobimetinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s002lbl.pdf. Published 2018. Accessed 23 June 2018
  50. 50.
    FDA XALKORI® (crizotinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202570s023lbl.pdf. Published 2018. Accessed 23 June 2018
  51. 51.
    FDA TAFINLAR® (dabrafenib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf. Published 2018. Accessed 23 June 2018
  52. 52.
    FDA IMFINZI® (durvalumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761069s002lbl.pdf. Published 2018. Accessed 23 June 2018
  53. 53.
    FDA TARCEVA (erlotinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Published 2016. Accessed 23 June 2018
  54. 54.
    FDA AFINITOR® (everolimus) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022334s040,203985s013lbl.pdf. Published 2018. Accessed 23 June 2018
  55. 55.
    FDA Fluorouracil highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012209s040lbl.pdf. Published 2016. Accessed 23 June 2018
  56. 56.
    FDA FASLODEX® (fulvestrant) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s035lbl.pdf. Published 2017. Accessed 23 June 2018
  57. 57.
    FDA IRESSA (gefitinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206995s000lbl.pdf. Published 2015. Accessed 23 June 2018
  58. 58.
    FDA GLEEVEC® (imatinib mesylate) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021588s052lbl.pdf. Published 2017. Accessed 23 June 2018
  59. 59.
    FDA CAMPTOSAR (Irinotecan) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf. Published 2014. Accessed 23 June 2018
  60. 60.
    FDA TYKERB® (lapatinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022059s022lbl.pdf. Published 2017. Accessed 23 June 2018
  61. 61.
    FDA Femara (letrozole) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf. Published 2018. Accessed 23 June 2018
  62. 62.
    FDA NERLYNX (neratinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf. Published 2017. Accessed 23 June 2018
  63. 63.
    FDA ZEJULA (niraparib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf. Published 2017. Accessed 23 June 2018
  64. 64.
    FDA OPDIVO (nivolumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s058lbl.pdf. Published 2018. Accessed 23 June 2018
  65. 65.
    FDA. LYNPARZA® (olaparib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206162s008lbl.pdf. Published 2017. Accessed 23 June 2018
  66. 66.
    FDA LARTRUVO (olaratumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf. Published 2016. Accessed 23 June 2018
  67. 67.
    FDA TAGRISSO® (osimertinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf. Published 2018. Accessed 23 June 2018
  68. 68.
    FDA IBRANCE® (palbociclib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207103s007lbl.pdf. Published 2018. Accessed 23 June 2018
  69. 69.
    FDA VECTIBIX® (panitumumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125147s207lbl.pdf. Published 2017. Accessed 23 June 2018
  70. 70.
    FDA VOTRIENT® (pazopanib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022465s024s025lbl.pdf. Published 2017. Accessed 23 June 2018
  71. 71.
    FDA KEYTRUDA® (pembrolizumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s043lbl.pdf. Published 2018. Accessed 23 June 2018
  72. 72.
    FDA PERJETA® (pertuzumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf. Published 2017. Accessed 23 June 2018
  73. 73.
    FDA KISQALI® (ribociclib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf. Published 2017. Accessed 23 June 2018
  74. 74.
    FDA RUBRACA® (rucaparib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf. Published 2018. Accessed 23 June 2018
  75. 75.
    FDA Tamoxifen citrate, highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017970s054lbl.pdf. Published 2006. Accessed June 23 2018
  76. 76.
    FDA MEKINIST® (trametinib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114Orig1s009lbl.pdf. Published 2018. Accessed June 23 2018
  77. 77.
    FDA HERCEPTIN® (trastuzumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103792s5337lbl.pdf. Published 2017. Accessed June 23 2018
  78. 78.
    FDA ZELBORAF® (vemurafenib) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf. Published 2017. Accessed June 23 2018
  79. 79.
    FDA Table of pharmacogenomic biomarkers in drug labeling last updated: 12/2017. Food and Dug Administration. https://www.fda.gov/downloads/drugs/scienceresearch/ucm578588.pdf. Published 2017. Accessed June 23 2018

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • María Luisa Romero Lagunes
    • 1
  • Francisco Emilio Vera Badillo
    • 1
    • 2
    Email author
  1. 1.University Center Against Cancer, Autonomous University of Nuevo LeonMonterreyMexico
  2. 2.Department of Oncology, Canadian Cancer Trials GroupQueen’s UniversityKingstonCanada

Personalised recommendations